FindTrial
Sign In

Nivolumab plus Ipilimumab

DRUG5 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Canadian Cancer Trials Group, Fondazione Ricerca Traslazionale, Institut Bergonié, Bristol-Myers Squibb

Conditions

Advanced Solid TumorsBladder CancerCancer Treated With Immune-checkpoint InhibitorsLymphoma, Non-HodgkinMelanomaMultiple MyelomaSquamous-Cell Lung CancerUnresectable Hepatocellular Carcinoma

Phase 2

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
CompletedNCT02553642
Memorial Sloan Kettering Cancer CenterBladder Cancer, Melanoma
Start: 2015-09-14End: 2024-04-29Updated: 2025-07-22
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
RecruitingNCT03297606
Canadian Cancer Trials GroupAdvanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
Start: 2018-03-23End: 2027-01-31Target: 720Updated: 2026-03-27
An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)
NCT03823625
Fondazione Ricerca TraslazionaleSquamous-Cell Lung Cancer
Start: 2017-09-13End: 2021-02-28Target: 112Updated: 2020-03-25

Unknown Phase

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)
CompletedNCT03963518
Institut BergoniéCancer Treated With Immune-checkpoint Inhibitors
Start: 2017-01-31End: 2020-12-31Updated: 2025-10-06
First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
RecruitingNCT07679061
Bristol-Myers SquibbUnresectable Hepatocellular Carcinoma
Start: 2026-03-05End: 2028-02-29Target: 200Updated: 2026-07-01

Related Papers

MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Clinical Cancer Research2025-01-211 citations
Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO).
Journal of Clinical Oncology2024-06-011 citations
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
BMC Cancer2023-02-2223 citations
Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.
Journal of Clinical Oncology2019-05-201 citations
Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC).
Journal of Clinical Oncology2019-03-015 citations
Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.
Journal of Clinical Oncology2019-01-291 citations
Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.
Journal of Clinical Oncology2018-05-2018 citations
Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
Journal of Clinical Oncology2017-02-209 citations